Low Uptake of FDA-Approved RSV Vaccine Among Older Adults Linked to Access and Awareness Barriers

A recent analysis highlights low uptake of the respiratory syncytial virus (RSV) vaccine among older adults, despite its approval by the U.S. Food and Drug Administration (FDA). Heidi De Souza, MPH, has identified significant disparities and barriers that limit access to the vaccine and hinder awareness among this population.

The findings point to challenges in ensuring equitable distribution and education about the RSV vaccine following its FDA approval. Older adults, who are at higher risk for severe RSV-related illness, face obstacles such as limited availability, lack of awareness about the vaccine’s benefits, and potential logistical issues in accessing vaccination services. These factors contribute to a slower adoption rate within this vulnerable demographic. The report underscores ongoing gaps in public health efforts to address these barriers effectively.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 19, 2025

Author

GOAI